FibroGen, Inc. (FGEN), a biotechnology company, said on Monday that it has appointed David DeLucia as Chief Financial Officer with effect from December 16 to replace Juan Graham, who stepped down on December 15.
Most recently, DeLucia served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury.
Prior to joining FibroGen in 2022, he held roles of increasing responsibility at TherapeuticsMD, overseeing Financial Planning and Analysis, Corporate Development, and Investor Relations.
For comments and feedback: editorial@rttnews.com